-
Published06/11/2024
-
Today08/12/2024
-
Deadline31/10/2026
-
Opening of tenders02/11/2026
Utilities
- indicates text translated automatically in your browsing language
Conclusion of non-exclusive discount agreements pursuant to §§ 130a(8)/130c(1) SGB V on medicinal products with the active substance fluorouracil, combinations (D11AF55) in the context of a so-called open-house model. Text automatically translated in your browsing language Automatically translated
Conclusion of non-exclusive discount agreements pursuant to §§ 130a(8)/130c(1) SGB V on medicinal products with the active substance fluorouracil, combinations (D11AF55) within the period from 01.01.2025 to 31.12.2026 with the possibility of concluding the contract at any time (open-house model). In the open house procedure, medicinal products are excluded in accordance with the BfArM list pursuant to § 35(5a) SGB V (Pediatric Medicinal Products). Text automatically translated in your browsing language Automatically translated
sen-info
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.